S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NASDAQ:OVID

Ovid Therapeutics - OVID Stock Forecast, Price & News

$2.43
-0.02 (-0.82%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.43
$2.48
50-Day Range
$1.66
$2.53
52-Week Range
$1.40
$3.55
Volume
44,219 shs
Average Volume
61,728 shs
Market Capitalization
$171.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Ovid Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
2.9% Upside
$2.50 Price Target
Short Interest
Healthy
0.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.79) to ($0.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

865th out of 1,028 stocks

Pharmaceutical Preparations Industry

428th out of 501 stocks

OVID stock logo

About Ovid Therapeutics (NASDAQ:OVID) Stock

Ovid Therapeutics, Inc. is a biopharmaceutical company, engaged in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OVID Stock News Headlines

Belharra Therapeutics Debuts With $130 Million in Funding
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
REAL,COMM and OVID among after hour movers
Ovid Therapeutics: Q1 Earnings Insights
Ovid Therapeutics GAAP EPS of -$0.38 misses by $0.22
See More Headlines
Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OVID Company Calendar

Last Earnings
11/08/2022
Today
2/04/2023
Next Earnings (Estimated)
3/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OVID
Fax
N/A
Employees
57
Year Founded
2014

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$2.50
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+2.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$122.83 million
Pretax Margin
-4,736.61%

Debt

Sales & Book Value

Annual Sales
$1.46 million
Cash Flow
$1.79 per share
Book Value
$2.64 per share

Miscellaneous

Free Float
62,927,000
Market Cap
$171.23 million
Optionable
Not Optionable
Beta
1.15

Social Links


Key Executives

  • Jeremy Max Levin
    Chairman, President & Chief Executive Officer
  • Jason Tardio
    Chief Operating Officer
  • Jeffrey A. Rona
    Chief Financial & Business Officer
  • Claude Nicaise
    Head-Research & Development
  • Julia Tsai
    Senior VP-Clinical Development & Medical Affairs













OVID Stock - Frequently Asked Questions

Should I buy or sell Ovid Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OVID shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View OVID analyst ratings
or view top-rated stocks.

What is Ovid Therapeutics' stock price forecast for 2023?

1 analysts have issued 12 month target prices for Ovid Therapeutics' stock. Their OVID share price forecasts range from $2.50 to $2.50. On average, they expect the company's share price to reach $2.50 in the next year. This suggests a possible upside of 2.9% from the stock's current price.
View analysts price targets for OVID
or view top-rated stocks among Wall Street analysts.

How have OVID shares performed in 2023?

Ovid Therapeutics' stock was trading at $1.86 at the start of the year. Since then, OVID shares have increased by 30.6% and is now trading at $2.43.
View the best growth stocks for 2023 here
.

When is Ovid Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our OVID earnings forecast
.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) announced its earnings results on Tuesday, November, 8th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.01 million for the quarter.

What other stocks do shareholders of Ovid Therapeutics own?
When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amit Rakhit, Jason Tardio and Jeremy M Levin.
View institutional ownership trends
.

How do I buy shares of Ovid Therapeutics?

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $2.43.

How much money does Ovid Therapeutics make?

Ovid Therapeutics (NASDAQ:OVID) has a market capitalization of $171.23 million and generates $1.46 million in revenue each year. The company earns $122.83 million in net income (profit) each year or ($0.99) on an earnings per share basis.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The official website for the company is www.ovidrx.com. The company can be reached via phone at (646) 661-7661 or via email at investors@ovidrx.com.

This page (NASDAQ:OVID) was last updated on 2/5/2023 by MarketBeat.com Staff